<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90749">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01949753</url>
  </required_header>
  <id_info>
    <org_study_id>PV4398</org_study_id>
    <nct_id>NCT01949753</nct_id>
  </id_info>
  <brief_title>Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder</brief_title>
  <acronym>P-EX</acronym>
  <official_title>Influence of Pregnenolone on Distress and Autonomic Parameters During Cognitive-behavioral Exposure Therapy in Patients With Obsessive-compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Characterization of the influence of pregnenolone vs. placebo on subjective distress and
      autonomic functioning during cognitive-behavioral exposure therapy in patients with
      obsessive-compulsive disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Subjective units of distress (SUD)</measure>
    <time_frame>During exposure therapy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low/high frequency index of heart rate variability (L/HFI)</measure>
    <time_frame>During exposure therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Salivary cortisol, noradrealine, pregnenolone; heart rate, blood pressure</measure>
    <time_frame>During exposure therapy</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obsessive-compulsive Disorder (OCD)</condition>
  <arm_group>
    <arm_group_label>Nutritional supplement Pregnenolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally two hours before exposure therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutritional supplement Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pregnenolone</intervention_name>
    <arm_group_label>Nutritional supplement Pregnenolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -OCD according to DSM-IV criteria.

        Exclusion Criteria:

          -  Acute suicidality

          -  psychotic disorders,

          -  bipolar disorder

          -  substance dependency

          -  organic brain disorder

          -  pregnancy

          -  lactation

          -  tuberculosis

          -  gastric/duodenal ulcer

          -  diabetes mellitus

          -  acute inflammation

          -  autoimmune disorders

          -  arterial hypertension

          -  therapy with glucocorticoids (up to 4 weeks ago)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kellner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kellner, MD, PhD</last_name>
    <email>kellner@uke.uni-hamburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Kellner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 23, 2013</lastchanged_date>
  <firstreceived_date>September 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obsessive-compulsive disorder (OCD)</keyword>
  <keyword>Exposure therapy</keyword>
  <keyword>Extinction learning</keyword>
  <keyword>Pregnenolone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
